Document
false0000875045 0000875045 2020-06-03 2020-06-03


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2020
BIOGEN INC.
(Exact name of registrant as specified in its charter)
Delaware
0-19311
33-0112644
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

225 Binney Street, Cambridge, Massachusetts 02142
(Address of principal executive offices; Zip Code)
    
Registrant’s telephone number, including area code: (617) 679-2000

(Former name or former address, if changed since last report.)
    
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, $0.0005 par value
 
BIIB
 
The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 5.07     Submission of Matters to a Vote of Security Holders

On June 3, 2020, Biogen Inc. (the "Company") held its 2020 Annual Meeting of Stockholders. The final voting results for this meeting are as follows:

1.
Stockholders elected twelve nominees to the Board of Directors to serve for a one-year term extending until the 2021 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows:
Nominee
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
Alexander J. Denner
 
109,578,677

 
24,115,678

 
139,938

 
11,528,918

Caroline D. Dorsa
 
114,393,693

 
19,315,657

 
124,943

 
11,528,918

William A. Hawkins
 
116,756,044

 
16,923,793

 
154,456

 
11,528,918

Nancy L. Leaming
 
114,725,734

 
18,984,269

 
124,290

 
11,528,918

Jesus B. Mantas
 
114,803,547

 
18,888,530

 
142,216

 
11,528,918

Richard C. Mulligan
 
114,489,400

 
19,208,581

 
136,312

 
11,528,918

Robert W. Pangia
 
110,981,253

 
22,721,168

 
131,872

 
11,528,918

Stelios Papadopoulos
 
105,915,276

 
26,978,888

 
940,129

 
11,528,918

Brian S. Posner
 
114,139,581

 
19,556,217

 
138,495

 
11,528,918

Eric K. Rowinsky
 
106,914,175

 
26,782,624

 
137,494

 
11,528,918

Stephen A. Sherwin
 
116,603,647

 
17,082,790

 
147,856

 
11,528,918

Michel Vounatsos
 
114,368,788

 
19,205,777

 
259,728

 
11,528,918

  

2.
Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020, with the votes cast as follows:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
142,634,499
 
2,547,394
 
181,318
 


3.
Stockholders approved the advisory vote on executive compensation, with the votes cast as follows:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
110,965,295
 
22,518,791
 
350,207
 
11,528,918
 

Item 9.01     Financial Statements and Exhibits.
(d)    Exhibits
Exhibit No.
 
Description
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)








Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Biogen Inc.
By: /s/ F. Ty Edmondson                 
F. Ty Edmondson
Chief Corporate and Compliance Counsel and Assistant Secretary
Date: June 5, 2020



v3.20.1
Cover Page
Jun. 03, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 03, 2020
Entity Registrant Name BIOGEN INC.
Entity Incorporation, State or Country Code DE
Entity File Number 0-19311
Entity Tax Identification Number 33-0112644
Entity Address, Address Line One 225 Binney Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 679-2000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0005 par value
Trading Symbol BIIB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000875045
Amendment Flag false